Neuromuscular Adverse Events Associated with Anti-PD-1 Monoclonal Antibodies
Neurol 92:663-674, Johansen, A.,et al, 2019
Inflammatory Muscle Diseases
NEJM 372:1734-1747, Dalakas, M.C., 2015
Diagnostic Evaluation of Clinically Normal Subjects with Chronic hyperCKemia
Neurol 66:1585-1587, Fernandez,C.,et al, 2006
Neurologic Manifestations in Primary Sjogren Syndrome: A Study of 82 Patients
Medicine 83:280-291, Delalande,S.,et al, 2004
Polymyositis
Neurol 61:316-321, van der Meulen,M.F.G.,et al, 2003
Polymyositis and Dermatomyositis
Lancet 362:971-982, Dalakas,M.C.&Hohlfeld,R., 2003
Magnetic Resonance Imaging of the Forearm as a Diagnostic Aid in Pts with Sporadic Inclusion Body Myositis
Neurol 48:863-866, Sekul,E.A.,et al, 1997
Inclusion Body Myositis
JNNP 60:251-255, Garlepp,M.J.&Mastaglia,F.L., 1996
Inclusion Body Myositis:Clinical and Pathological Boundaries
Ann Neurol 40:581-586, Amato,A.A.,et al, 1996
Polymyositis, Dermatomyositis, and Inclusion-Body Myositis
NEJM 325:1487-1498, Dalakas,M.C., 1991
Pterygoid Myositis Mimicking Giant Cell Arteritis
Neurol 92:e2297, Na, S.,et al, 2019
The Neurologic Complications of Scleromyxedema
Medicine 80:313-319, Berger,J.R.,et al, 2001
Weak at the Knees
Lancet 354:1696, Webster,G.&Beynon,H., 1999
The Therapeutic Dilemma of Inclusion Body Myositis
Neurol 48:567-568, Barohn,R.J., 1997
Fibrodysplasia Ossificans Progressiva, The Clinical Features & Natural Hx of 34 Pts
J Bone Joint Surg 64B:76-83, Connor,J.M.&Evans,D.A.P., 1982